Gary Rabin
Gary Rabin has a 25-year career in finance and operations that primarily encompasses investing in, managing and capital-raising for small-cap and emerging growth companies.
(read full bio)
Official Advanced Cell Technology, Inc social media
Timing and Pace of Our Clinical Trials
Greetings, As you are undoubtedly aware, last July we initiated the first-ever clinical trials using a cell therapy derived from human embryonic stem cells (hESCs) to treat various forms of macular degeneration. [...]
Clinical Trials, Results, and Timing
Greetings, For many of us, the New Year is a time not just for looking forward but for reflecting on events, achievements and lessons learned over the past year. I anticipate an amazing year ahead for ACT, and at [...]
Settlements, Proxy, and Looking Ahead
Greetings, You have no doubt seen our recent 8K filing and press release about the settlements and the filing of the preliminary proxy. In this blog post I would like to add a bit of color on these topics and also [...]
Reflecting on the EU Court Ruling: A Setback for European ESC Field, But Not for ACT
Greetings, As you may have heard in the news, or read about in the press release we issued, the European Court of Justice just ruled that inventions based on the use of human embryonic stem cells (hESCs) for [...]
ACT’s Director of Regulatory Affairs Edmund Mickunas to Present at Phacilitate Cell & Gene Therapy Forum in Singapore; Reflects Growing Interest in Company and Its Programs in East Asia
Greetings, ACT’s Director of Regulatory Affairs, Edmund “Ed” Mickunas, will be presenting on the company’s behalf at a major industry conference, the “Phacilitate Cell & Gene Therapy Forum Asia [...]
(No commercial advertising involvement of any kind has been solicited or accepted in the authorship of the content within a Chairman's company blog.
Advertising placed on this website is not endorsed or affiliated with authors, the chairmen, CEO's, or their respective companies.)